Oncolytics Biotech Inc ONCY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.47
- Day Range
- $0.45–0.50
- 52-Week Range
- $0.45–1.32
- Bid/Ask
- $0.48 / $0.49
- Shares Outstanding
- 131.12M
- Market Cap
- $61.14M
- Volume/Avg
- 3M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
Valuation
|
Metric
|
ONCY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ONCY
|
|---|---|
Quick Ratio | 1.02 |
Current Ratio | 1.35 |
Interest Coverage | — |
Quick Ratio
ONCY
Profitability
|
Metric
|
ONCY
|
|---|---|
Return on Assets (Normalized) | −349.07% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ONCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!N^w@Q | LOCK|?#mZb | $129B | |||
| Moderna Inc
MRNA
| LOCK|<>Y&<L | LOCK|b!$ | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^d<!?T | LOCK|BJ$!z | $79B | |||
| argenx SE ADR
ARGX
| LOCK|!@vJ#y | LOCK|D^ | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|g^G##! | LOCK|!q | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vpyBVL | LOCK|hdZ<< | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|h&%$L!h | LOCK|ss!D? | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|dgz^x$k | LOCK|qFc | $24B | |||
| Incyte Corp
INCY
| LOCK|jb&?fvc | LOCK|ryV | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#Fm?BF | LOCK|@Y | $14B |
United States